These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 27865798

  • 1. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A, DeNichilo MO, Panagopoulos V, Zinonos I, Liapis V, Hay S, Ingman W, Ponomarev V, Atkins G, Findlay D, Zannettino A, Evdokiou A.
    Cancer Lett; 2017 Feb 01; 386():141-150. PubMed ID: 27865798
    [Abstract] [Full Text] [Related]

  • 2. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
    Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, Touraine JL, Clézardin P.
    Cancer Res; 2011 Jul 01; 71(13):4562-72. PubMed ID: 21646473
    [Abstract] [Full Text] [Related]

  • 3. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB.
    J Cancer Res Clin Oncol; 2015 Jun 01; 141(6):1025-36. PubMed ID: 25431338
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
    Liu M, Sun LL, Li YJ, Li HY, Zhang J, Li BH, Ye ZM.
    Int Immunopharmacol; 2015 Sep 01; 28(1):160-7. PubMed ID: 26071219
    [Abstract] [Full Text] [Related]

  • 5. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
    Sun L, Li Y, Jiang Z, Zhang J, Li H, Li B, Ye Z.
    Tumour Biol; 2016 Jun 01; 37(6):7333-44. PubMed ID: 26676633
    [Abstract] [Full Text] [Related]

  • 6. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J, Clézardin P.
    Clin Cancer Res; 2012 Nov 15; 18(22):6249-59. PubMed ID: 23032740
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Mattarollo SR, Kenna T, Nieda M, Nicol AJ.
    Cancer Immunol Immunother; 2007 Aug 15; 56(8):1285-97. PubMed ID: 17265022
    [Abstract] [Full Text] [Related]

  • 8. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
    Dhar S, Chiplunkar SV.
    Cancer Immun; 2010 Nov 12; 10():10. PubMed ID: 21069948
    [Abstract] [Full Text] [Related]

  • 9. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.
    Cytotherapy; 2013 Apr 12; 15(4):481-91. PubMed ID: 23391461
    [Abstract] [Full Text] [Related]

  • 10. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
    Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F.
    Cancer Immunol Immunother; 2010 Nov 12; 59(11):1611-9. PubMed ID: 20582413
    [Abstract] [Full Text] [Related]

  • 11. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
    Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, Agrati C, Amendola A, Abdeddaim A, Vlassi C, Malkovsky M, D'Offizi G.
    AIDS; 2009 Mar 13; 23(5):555-65. PubMed ID: 19238075
    [Abstract] [Full Text] [Related]

  • 12. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE, Harhash AA, Kozlow WM, Waning DL, Regan JN, She Y, John SK, Murthy S, Niewolna M, Marks AR, Mohammad KS, Guise TA.
    Oncotarget; 2017 Jan 31; 8(5):8406-8419. PubMed ID: 28039445
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
    Di Carlo E, Bocca P, Emionite L, Cilli M, Cipollone G, Morandi F, Raffaghello L, Pistoia V, Prigione I.
    Mol Ther; 2013 May 31; 21(5):1034-43. PubMed ID: 23481325
    [Abstract] [Full Text] [Related]

  • 14. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K.
    Cytotherapy; 2008 May 31; 10(8):842-56. PubMed ID: 19016372
    [Abstract] [Full Text] [Related]

  • 15. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG, Kanakis I, Gialeli Ch, Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN, Karamanos NK.
    Biochim Biophys Acta; 2013 Jun 31; 1830(6):3625-34. PubMed ID: 23395844
    [Abstract] [Full Text] [Related]

  • 16. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A.
    Clin Cancer Res; 2009 May 15; 15(10):3451-61. PubMed ID: 19401351
    [Abstract] [Full Text] [Related]

  • 17. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL, Ottewell PD.
    Clin Exp Metastasis; 2016 Mar 15; 33(3):211-24. PubMed ID: 26585891
    [Abstract] [Full Text] [Related]

  • 18. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
    Li Z, Tang J, Sun L, Ye Z.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan 15; 29(1):6-9. PubMed ID: 23294710
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
    Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, Yang J, Hu Y, Chen Y, Lin L, Hao J, Li J, Chen J, Li M, Wu Q, Peters C, Zhou Q, Li J, Liang Y, Wang X, Han B, Ma M, Kabelitz D, Xu K, Tu W, Wu Y, Yin Z.
    Cell Mol Immunol; 2021 Feb 15; 18(2):427-439. PubMed ID: 32939032
    [Abstract] [Full Text] [Related]

  • 20. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
    Arkko S, Zlatev HP, Mönkkönen H, Räikkönen J, Benzaïd I, Clézardin P, Mönkkönen J, Määttä JA.
    Cancer Lett; 2015 Feb 01; 357(1):279-285. PubMed ID: 25444923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.